Indegene FY26 Revenue Climbs 23.6%, PAT Falls Amid Client Growth

Indegene Ltd. reported its fiscal year 2026 results, with revenue from operations climbing 23.6% year-over-year to ₹35,105 million. The company’s fourth quarter (Q4 FY26) also showed strong performance, with revenue increasing 32.8% from the previous year to ₹10,034 million.

Despite this top-line expansion, profit after tax (PAT) for FY26 saw a marginal decrease of 1.4%, settling at ₹4,011 million. The Q4 FY26 PAT declined 32.3% year-over-year to ₹797 million.

Indegene ended FY26 with 91 active clients. Notably, the number of clients contributing over $1 million each in revenue grew by 29% year-over-year, reaching 53 such accounts.

Strategic Importance

The significant revenue increase reflects strong demand for Indegene's digital solutions within the life sciences sector. Growth in high-value clients suggests successful relationship deepening and wider adoption of services. However, the profit dip, particularly in Q4, points to potential cost pressures or investments, even as the company focuses on areas like Generative AI.

Company Background

Indegene is a digital-first specialist for global life sciences companies, providing solutions for commercialization, medical affairs, and clinical development. Its goal is to drive digital transformation for biopharmaceutical and medical device clients using AI and data analytics. The company has focused on increasing revenue per employee through technology, aiming for double-digit growth. Challenges that impacted FY25 growth are now reported to be resolved.

Investor Outlook

Shareholders can anticipate continued focus on revenue growth through client acquisition and deeper engagement, especially with high-value accounts. Indegene's position in Generative AI is seen as a key future growth driver. Investors will monitor cost management and margin improvement efforts to understand the PAT trend. A final dividend of ₹2.25 per share, a 12.5% increase from FY25, has been recommended.

Key Risks

The decline in PAT, especially in Q4, requires monitoring. Persistent margin pressure could affect overall profitability despite revenue gains.

Competitive Landscape

Indegene competes with global firms like IQVIA, Syneos Health, and Veeva Systems in the life sciences digital solutions market. Its specialized digital-first approach and deep life sciences focus, leveraging AI, serve as key differentiators.

Performance Metrics

By the end of FY26, Indegene's active client base reached 91. Revenue per employee increased to $74.7K. As of March 31, 2026, the company held ₹15,385 million in cash and cash equivalents.

Looking Ahead

Investors will be tracking quarterly updates on client acquisition, growth in $1 million+ revenue clients, and management commentary on margin improvement strategies and Generative AI investments. Further details on the Q4 FY26 PAT decline and the FY27 outlook, including guidance, will be closely watched. Performance of specific segments like Enterprise Commercial Solutions (ECS) and any strategic partnerships will also be key.